New research published in JAMA finds a deep concentration of PBM services are evident across all three payer markets, especially Medicare Part D.

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to the FTC’s stalemate 2-2 vote today, which would have supported study of the competitive impact of contractual provisions, reimbursement adjustments, and other PBM practices affecting drug prices, including those practices that may disadvantage independent or specialty pharmacies.